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Abstract Despite the increasing availability of direct-to-
consumer (DTC) genetic testing, it is currently unclear
how such services are regulated in Europe, due to the lack
of EU or national legislation specifically addressing this
issue. In this article, we provide an overview of laws that
could potentially impact the regulation of DTC genetic
testing in 26 European countries, namely Austria,
Belgium, Cyprus, the Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary,
Ireland, Italy, Latvia, Lithuania, Luxembourg, Norway,
Poland, Portugal, Romania, Slovakia, Slovenia, Spain,
Sweden, the Netherlands and the United Kingdom.
Emphasis is placed on provisions relating to medical su-
pervision, genetic counselling and informed consent. Our
results indicate that currently there is a wide spectrum of
laws regarding genetic testing in Europe. There are coun-
tries (e.g. France and Germany) which essentially ban
DTC genetic testing, while in others (e.g. Luxembourg
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and Poland) DTC genetic testing may only be restricted
by general laws, usually regarding health care services
and patients’ rights.
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Introduction
Since the 1960s, genetic tests have been provided to patients
for health-related reasons within a clinical setting (Sanfilippo
et al. 2015), usually following a medical referral, genetic
counselling, and upon obtaining informed consent.
However, in the last decade, a wide variety of direct-to-
consumer (DTC) genetic tests have also been made available
by commercial companies with varying involvement of
healthcare professionals. In some cases, genetic tests are ad-
vertised DTC, but then ordered by a healthcare provider, who
may also be the recipient of the test results; in other cases, tests
are advertised, sold and delivered DTC without any involve-
ment of a medical professional (Hogarth et al. 2008). In the
latter case, the consumer usually orders a genetic test online.
Subsequently, he/she receives a testing kit at home to collect a
biological sample (which, depending on the test, usually com-
prises of an accumulated volume of saliva or hair). After send-
ing the biological sample to the company, genetic material is
extracted from it, and the DNA is analysed. A few weeks later,
the consumer is provided with the test results, which are sent
to him/her either via email or upon accessing a secure website
(Kalokairinou et al. 2014).
Currently, a large number of both health-related and non-
health-related genetic tests is available directly to consumers
(Phillips 2016). The former group includes diagnostic tests for
monogenic diseases such as cystic fibrosis, susceptibility tests
for common complex disorders such as cardiovascular disease
and diabetes, carrier tests for X-linked and recessive disorders,
as well as pharmacogenomic and nutrigenomic tests. Non-
health-related tests include ancestry tests, athletic performance
tests, matchmaking tests and tests for ‘fun’ traits, such as ear
wax type and eye colour (EASAC and FEAMWorking Group
2012).
This model of providing genetic testing has been very con-
troversial among stakeholders over the past years. On the one
hand, proponents have been underlining that DTC genetic
testing enhances the autonomy of consumers (Vayena 2015)
and allows them to be in charge of their healthcare manage-
ment (Marietta and Mcguire 2009), all without the intermedi-
ary of doctors and longwaiting lists for hospital appointments.
Furthermore, it has been argued that consumers have a right to
their genetic information (Su et al. 2013) and that, by
circumventing the public healthcare system, the privacy of
genetic data may be better protected against insurers and
employers.
On the other hand, this model of providing genetic tests has
also been subject to criticism. The absence of medical super-
vision and genetic counselling often encountered in the com-
mercial setting has raised concerns regarding potential misin-
terpretation of test results by consumers, which may lead to
unnecessary distress and/or inappropriate healthcare decision
making (Howard and Borry 2012). Moreover, it has been
claimed that information accompanying the tests are often
misleading or inadequate, reducing informed consent to mere-
ly ticking a box (Hogarth et al. 2008). Further concerns focus
on the unproven or unclear clinical validity and utility of many
of the tests offered DTC (Bunnik et al. 2011; European
Society of Human Genetics 2010) the potential inappropriate
testing of minors (Howard et al. 2011), surreptitious testing of
third parties (Tamir 2010), endangering the privacy of genetic
data, especially in cases of company bankruptcy or change of
ownership (Zawati et al. 2011) and downstream costs to the
healthcare system from inappropriate follow-up visits to
healthcare professionals (Giovanni et al. 2010). This argument
is mostly prevalent in countries with a national tax based
funded healthcare system.
Of particular importance is that the rapid advance of
genotyping technologies and their decreasing costs have made
DTC tests increasingly available to consumers, outpacing the
development of effective regulation of such commercial ser-
vices (Grimaldi et al. 2011). Especially with regard to Europe,
currently, to the best of our knowledge, there is no EU or
national legislative instrument, specifically regulating DTC
genetic testing. As a result, different aspects of genetic testing
may be regulated by separate and sometimes overlapping le-
gal instruments on the national, EU or international level.
Laws affecting the regulation of DTC genetic testing on the
EU level include consumers’ protection laws and more spe-
cific laws on in vitro diagnostic (IVD) medical devices. For
example, the Unfair Commercial Practices Directive 2005/29
EC (European Parliament and the Council of the EU 2005)
aims to protect consumers from misleading actions and omis-
sions, as well as from aggressive commercial practices coming
from traders, such as emotional pressure or deceptive adver-
tising (European Commission 2016). In addition, genetic tests
with a medical purpose are considered IVD medical devices
and, in addition to being subject to consumer protection laws,
their safety and efficiency are also regulated by stricter laws
compared to common commercial goods. More specifically,
the Directive 98/79 EC on In Vitro Diagnostic Medical
Devices (European Parliament and the Council of the EU
1998) aims to ensure that all such devices entering the
European market are safe and efficient. This Directive (which
will be replaced by a new Regulation in May 2022) deals,
among others, with issues of analytical and, arguably, clinical
validity of genetic tests, as well as labelling.
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Moreover, there are aspects of genetic testing that go be-
yond the regulation of genetic tests as products and into the
realm of services, such as the provision of appropriate medical
supervision and genetic counselling, including the informed
consent process. While the existing EU regulatory framework
covers, to a large extent, genetic tests as products, the regula-
tion of aspects of genetic testing akin to services is not granted
the same level of control (Nicol et al. 2016). The provision of
genetic tests in Europe has traditionally been seen as directly
linked to the healthcare services and has been regulated most-
ly on the national level (Godard et al. 2003). Many European
countries restrict the framework within which genetic tests are
provided to patients by regulating the type of tests that may be
offered to the public, the type of facilities where genetic tests
may take place and the qualifications of the personnel offering
such testing.
To this end, some countries implement biomedical and/or
bioethical regulation [such as Norway (Bioteknologiloven
2003), Spain (Boletín Oficial del Estado No159 2007) and
France (LOI n° 2011–814 2011)1)]; others provide laws spe-
cif ic to genet ics (Soini 2012) , [such as Austr ia
(Gentechnikgesetz 1994), Germany (Gendiagnostikgesetz
2009),2 Hungary (Genetikai törvény 2008) and Sweden (Lag
(2006:351) 2006, Chapter 1, Section 1)] or address genetics
within more general laws on issues related to healthcare [such
as the Czech Republic (Act No. 373/2011 Coll. 2011), Ireland
(Disability Act 2005) and Lithuania (Civil Code of the
Republic of Lithuania 2000, Art. 6.725)]. In countries where
the process of genetic testing is not regulated by specific laws
or provisions, as long as such tests are considered to be health
services, relevant legislation may apply [for example in
Denmark (Danish Act on Health 2016), and Slovenia
(Health Care and Insurance Act 1992)], as well as regulation
related to patient rights (European Commission 2002) and
healthcare professionals’ duties (available in most countries).
The regulation of the framework within which the tests are
provided, and, more specifically, issues related to appropriate
medical supervision, genetic counselling and adequate in-
formed consent process, may also be influenced by interna-
tional documents such as the Convention on Human Rights
and Biomedicine (Oviedo Convention), issued by the Council
of Europe and its Additional Protocol on Genetic Testing for
Health Purposes, which is the first international binding doc-
ument (upon ratification) specifically addressing genetic test-
ing (Lwoff 2009). The Oviedo Convention, which aims at
protecting human dignity and identity and sets out
fundamental principles applicable to daily medical practice
(Council of Europe 1997), restricts (as it will be elaborated
below) the use of predictive, carrier and predisposition genetic
tests to health purposes or scientific research linked to health
purposes and it mandates genetic counselling for these tests.
The Additional Protocol on Genetic Testing for Health
Purposes (Council of Europe 2008) touches upon issues of
clinical utility, medical supervision, genetic counselling and
informed consent in the context of genetic testing. It has been
both signed and ratified by only four members of the Council
of Europe, namely Moldova, Montenegro, Norway and
Slovenia (Council of Europe 2017a). In addition, in October
2017, the Additional Protocol was also signed by the
Czech Republic, which is determined to ratify it (Council of
Europe 2017b). However, until the Additional Protocol has
been ratified by a fifth country, it cannot come into force,
since, this requires at least five ratifications (Council of
Europe 2008).
The different above-mentioned regulatory approaches have
resulted in a fragmented landscape when it comes to the reg-
ulation of DTC genetic testing. In this article, we provide an
overview of the wide spectrum of national laws regulating
genetic tests which could potentially impact DTC genetic test-
ing in 26 European countries. Particular emphasis is placed on
provisions relating to three specific issues: medical supervi-
sion, genetic counselling and informed consent. Furthermore,
the desirability of adopting a harmonized regulatory frame-
work across Europe with regard to these issues is discussed
in the light of the recent adoption of the EU Regulation on
IVD medical devices and the debate that preceded its
adoption.
Methods
Experts in health law and/or regulation of genetic testing from
countries where the Regulation on IVD medical devices will
apply (i.e. EU Member States, the countries of the European
Free Trade Association and Turkey) were contacted by LK,
HCH and PB and invited to contribute to this study. Experts
were asked to answer questions regarding national laws perti-
nent to the regulatory control of DTC genetic testing services
in the country where they have an expertise on the legal frame-
work. Particular emphasis was placed on whether medical
supervision and genetic counselling are mandatory and
whether there are specific requirements for informed consent
in the context of genetic testing.
Each collaborator’s answers constituted what we refer to,
as a ‘national report’ which was returned to LK, who then
analysed, summarized and grouped the legislations into cate-
gories based on similarities. Experts were then re-contacted in
order for them to clarify any details regarding their initial
answers, ensure the correct interpretation of their reports and
1 France can be considered to have a dual system where some provisions on
genetic testing are implemented in the bioethics law and others are implement-
ed in the civil code
2 An unofficial English translation can be retrieved from:
https://www.eshg.org/fileadmin/www.eshg.org/documents/Europe/
LegalWS/Germany_GenDG_Law_German_English.pdf [the English
translation is for information purposes only and has no legal force].
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the accuracy of the final text. All collaborators are co-authors
of this study. One exception to this approach is the information
included regarding Portugal; this information was largely
based on the description of the Portuguese legal context in
the article ‘Legislation on direct-to-consumer genetic testing
in seven European countries’ (Borry et al. 2012). The author
who contributed to that article is acknowledged herein.
Results
The results presented below focus on information regarding
the way medical supervision, genetic counselling and in-
formed consent in the context of genetic testing are regulated
in 26 different European countries. These countries are
Austria, Belgium, Cyprus, the Czech Republic, Denmark,
Estonia, Finland, France, Germany, Greece, Hungary,
Ireland, Italy, Latvia, Lithuania, Luxembourg, the
Netherlands, Norway, Poland, Portugal, Romania, Slovakia,
Slovenia, Spain, Sweden and the United Kingdom (UK).
Is medical supervision mandatory in the context of genetic
testing?
Medical supervision in the context of health-related genetic
testing has been assigned particular importance, as it aims to
assist patients in making informed healthcare choices and en-
sure that they have access to high-quality tests that are
Table 1 Countries requiring medical supervision
Country Types of tests requiring medical
supervision
Qualifications of medical professionals Statute
Austria GT providing information on:
• Carrier status,
• A risk of a disease,
• An existing disease
• A course of an illness or of a therapy
on man
Amedical specialist trained in human genetics or an
attending or a diagnosing medical specialist
Austrian Gene Technology Act Art.68 (1)
France GT for health purposes A geneticist or a non-geneticist familiar with the
medical situation of the patient who works in
close relationship with a center of reference
(1) Civil Code art. 16 (1)
(2) Arrété de bonnes pratiques juin 2013 art. 2.2
Germany GT for health purposes • Predictive genetic examinations: restricted to
physicians specialized in human genetics or other
specialized physicians qualified to conduct them
in their specialist area of practice
• Diagnostic genetic examinations: any physician
licensed to practice medicine
Genetic Diagnosis Act
Hungary GT conducted for:
• Prophylactic
• Diagnostic
• Therapeutic
• Rehabilitation purposes
• Research purposes based on health
reasons
Healthcare providers holding the operating license
stipulated in the Minister of Health, Social and
Family Affairs Decree on the professional
minimum conditions necessary for health care
provision
Act NoXXI of 2008 on the protection of human
genetic data and the regulation of human
genetic studies, research and biobanks art. 12
Italy • Pre-symptomatic GT
• Susceptibility GT
Not specified General Authorisation No. 8/2014 for the
Processing of Genetic Data
Lithuania GT for health purposes Physicians trained in human genetics Order No. V-220 issued on April 24, 2003 by
Minister of Health
The Netherlands High-risk diagnostic medical devices
(including tests for the diagnosis of
hereditary diseases, and predictive
genetic tests)
Doctor or a pharmacist Decree on In-Vitro Diagnostic Devices
Slovenia GT for health purposes Clinical Geneticist Act ratifying the Additional Protocol to the
Convention on Human Rights and
Biomedicine concerning Genetic Testing for
Health Purposes, Art. 7
Portugal GT for:
• The detection of heterozygosity status
of recessive diseases
• Presymptomatic diagnosis of
monogenic diseases
• Genetic susceptibility tests in healthy
individuals
Clinical geneticist Law 12/2005 of 26 January 2005, Art. 9.2
Spain GT for health purposes Performed by qualified personnel and carried in
certified centers)
Act 14/2007, art 56
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appropriate for them. In this regard, Article 7 of the Additional
Protocol on genetic testing for health purposes prescribes that
‘A genetic test for health purposes may only be performed
under individualized medical supervision’ (Council of
Europe 2008). Of the countries included in our study, only
Slovenia, Norway and recently the Czech Republic have
agreed to be bound by it. However, to date, none of these
countries have put into force provisions rendering health-
related genetic testing performed without medical supervision
illegal.
Ten of the countries included in our study prescribe man-
datory medical supervision and restrictions in the way some
genetic tests are performed (Table 1). These countries are
Austria, France, Hungary, Italy, Germany, Austria,
Lithuania, the Netherlands, Portugal and Spain. Despite not
having signed or ratified the Additional Protocol, these coun-
tries are, therefore, in line with Article 7.
More specifically, in France, tests can only be performed
for healthcare purposes, with a medical prescription and real-
ized by an authorized laboratory (Code Civil 2006, article 16-
10 and 16-11; Code de la santé piblicque 1953, article R.
1131-9 and R. 1131-14). The professional prescribing genetic
tests can be either a geneticist or a non-geneticist, as long as
he/she is familiar with the medical situation of the patient and
he/she works in close relationship with a reference centre
(Arrété de Bonnes Pratiques 2013, article 2.2). What distin-
guishes France from other countries with restrictive regulatory
frameworks when it comes to genetic testing, is that France
also introduces penalization of the users (i.e. consumers or-
dering a test outside the clinical setting). More specifically, the
infringement of this provision is punishable under the criminal
code by a fine of 3.750 euro (Borry et al. 2012).
In Hungary, genetic tests may only be performed by
healthcare providers3 (Genetic Act 2008, article 12) and only
for specific purposes based on health reasons, namely, for
prophylactic, diagnostic, therapeutic, rehabilitation or re-
search purposes (Genetic Act 2008, article 13). Similarly, in
Italy, pre-symptomatic and susceptibility tests are only permit-
ted for healthcare purposes and healthcare-related research
purposes (Italian General Authorization for the Processing of
Genetic Data 2014). These tests depend on medical prescrip-
tion and ex ante supervision should, therefore, take place.
InGermany, the Genetic Diagnosis Act (Gendiagnostikgesetz
2009) prescribes that, whenever a genetic examination is con-
ducted formedical purposes, supervision by a qualified physician
is mandatory. In this regard, a distinction is made between the
qualifications required by physicians conducting diagnostic ge-
netic examinations and those required by physicians conducting
predictive genetic examinations (sec. 7 para. 1). Namely, diag-
nostic genetic examinations may be performed by any physician
licensed to practice medicine, whereas predictive genetic exam-
inations may only be performed by physicians specialized in
human genetics or by other specialized physicians qualified dur-
ing their medical training to perform them in their specialist area
of practice. TheGeneticDiagnosisAct also stipulates that genetic
examinations for the purpose of clarifying a family relationship
can only be carried out by physicians or qualified non-medical
experts (sec. 17 para. 4).
In the Netherlands, according to the Decree on In Vitro
Diagnostic Devices (Besluit in-vitro diagnostica 2001),
‘high-risk diagnostic medical devices’ including tests for the
diagnosis of hereditary diseases, and predictive genetic tests
may not be supplied directly to the user without the interven-
tion of a doctor or pharmacist.
In addition, Austria (Gentechnikgesetz 1994, article 68.1),
Lithuania (Order No. V-220 2003), Portugal (Lei no 12/2005
2005) and Spain (Boletín Oficial del Estado No159 2007,
articl 56) confine the provision of most health-related genetic
tests in designated facilities and require supervision by a
healthcare professional.
In countries without specific legislation on genetic testing,
the question of whether DTC genetic testing could be defined
as a health service or as an informational/recreational/educa-
tional activity has a rather important impact on the way such
tests may be regulated across different European countries.
For example, inBelgium, sanctions could be imposed on an
illegal practice of medicine (Law on the Practice of Health
Care Professions 1967, article 3). Hence, if offering a DTC
genetic test would be considered to constitute practice of med-
icine, the Law on Patient Rights would apply and a physician
should be involved in the provision of the tests. However,
many DTC companies write in their ‘terms of services’ that
they are not practicing medicine, and that their tests should not
be considered medical information, but only serve ‘informa-
tional purposes’.
Similarly, in Denmark the application of the Act on
Authorisation of Healthcare Professionals is contingent to
whether DTC genetic tests are considered to be health services
or not. According to this Act, it is generally legal for layper-
sons without professional authorisation, to treat patients, pro-
vided they do not expose the patient to danger (Danish
Authorization Act 2016). However, certain kind of treatments
and procedures, outlined in section 74 of the Act may only be
carried out by (or under the supervision of) a medical doctor. If
laypersons’ treatment is not compliant with these rules, crim-
inal sanctions may be imposed. The procedures normally in-
volved in DTC genetic testing (mouth swab) are not listed as
one of the treatments or procedures exclusively assigned to
medical doctors. Consequently, it is only in situations where
the test exposes the patient to danger, that sanctions can be
employed.
3 These healthcare professionals should fulfil the material and personal con-
ditions and hold the operating license stipulated in the Minister of Health,
Social and Family Affairs Decree on the professional minimum conditions
necessary for healthcare provision.
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Is genetic counselling mandatory in the context of genetic
testing?
Similar to the goals of medical supervision, but with a more
specific process and aim, genetic counselling is a communica-
tion process aiming to support patients in taking informed
healthcare decisions, after understanding the benefits, limita-
tions and implications of a genetic test for themselves and their
family and being informed about available healthcare options.
Currently, there are 16 countries requiring genetic counsel-
ling for some types of genetic tests: Austria, Cyprus, the
Czech Republic, Estonia, Finland, France, Germany,
Greece, Hungary, Italy, Latvia, Lithuania, Norway, Slovakia,
Slovenia and Spain (Table 2).
The relevant legislation of some of these countries have been
influenced by the Convention for the Protection of Human
Rights and Dignity of the Human Being with regard to the
Application of Biology and Medicine: Convention on Human
Rights and Biomedicine (hereinafter Oviedo Convention) and,
more specifically, Article 12 on ‘Predictive genetic tests’.
Article 12 of the Oviedo Convention prescribes that
tests which are predictive of genetic diseases or which
serve either to identify the subject as a carrier of a gene
responsible for a disease or to detect a genetic predispo-
sition or susceptibility to a disease may be performed
only for health purposes or for scientific research linked
to health purposes, and subject to appropriate genetic
counselling (Council of Europe 1997).
Of the 26 countries included in our study, the following 16
have both signed and ratified the Oviedo Convention: Cyprus,
the Czech Republic, Denmark, Estonia, Finland, France,
Greece, Hungary, Latvia, Lithuania, Norway, Portugal,
Romania, Slovakia, Slovenia and Spain. The ratification of
the Convention creates the obligation for those countries to
introduce implementing legislation in their national law,
bringing it to conformity with the principles of the
Convention (Andorno 2005).
In France genetic counselling is mandatory and can be per-
formed either by a geneticist or a genetic counsellor (Arrété de
Bonnes Pratiques 2013). Similarly, in Spain (Boletín Oficial del
Estado No159 2007) and the Czech Republic (Act No. 373/
2011 Coll. 2011), when it comes to health-related genetic test-
ing, the patient must be guaranteed appropriate genetic counsel-
ling. In the case of Spain, the qualified professional who carries
out or coordinates the genetic counselling must provide ade-
quate information in relation to both the consequences of the
resulting genetic diagnosis, as well as the possible alternatives
available to the patient.
Under the Hungarian law (Parliamentary Act No XXI
2013), genetic counselling is also mandatory and is defined
as a consultation procedure during which a person authorised
by special legislation provides information on the advantages
or risks of human genetic studies, explores possible conse-
quences of the results of genetic studies and helps to under-
stand the nature of the illness.
In Greece (Law 2619/1998 1998, article 12) and Cyprus
(Law 31 (III)/2001 article 12), appropriate genetic counselling
is mandatory for predictive, carrier and predisposition genetic
tests. In Norway (Bioteknologiloven 2003) genetic counsel-
ling is compulsory when it comes to presymptomatic, predic-
tive and carrier test. On the same line, Slovenia (UL RS 17/98
1998, article 12), where national legislation regarding genetic
testing is currently being developed, all presymptomatic, pre-
dictive and prenatal genetic tests are performed with pre- and
post-test genetic counselling by a clinical geneticist.
Other countries, such as Denmark,4 Estonia, Finland,
Latvia, Lithuania, Slovakia and Romania, despite having
signed and ratified the Oviedo Convention, do not stipulate
explicitly in their national legislation that genetic counselling
should be mandatory for the provision of health-related genet-
ic testing. Nevertheless, in some of these countries (for in-
stance, in Estonia, Finland, Latvia, Lithuania and Slovakia)
ratified international treaties are directly applicable. Therefore,
the requirements regarding genetic counselling imposed by
Article 12 of the Oviedo Convention are applicable even with-
out being incorporated into national law (Eurogentest 2002).
Countries that have only signed but not ratified the Oviedo
Convention (so although they acknowledge the principles
underlined by the Convention, they have no obligation to
introduce its principles into their national law) are Italy,
Luxembourg, the Netherlands,5 Poland and Sweden.
In Italy, the Parliament has authorized the ratification
and has incorporated the Convention in the domestic sys-
tem, but has not yet deposited the instruments of ratifica-
tion. In this regard, in Italy, genetic counselling is man-
datory. This should be the case not only for health-related
genetic tests, but also for genetic tests informing on fam-
ily relationships. This is because based on the General
Authorisation No. 8/2014 for the Processing of Genetic
Data by the Data Protection Authority: ‘With regard to
processing operations carried out via genetic tests for
healthcare and/or family reunion purposes, genetic
counselling shall be provided to data subjects both before
and after performing the tests’ (I ta l ian General
Authorization for the Processing of Genetic Data 2014).
4 Despite the lack of laws mandating genetic counselling, providing such
consultations may be considered as part of a general obligation to provide
due care (section 17 of the Consolidating Act no. 1356 of 23 October 2016
on authorisation of healthcare professionals and on healthcare services)
5 However, recently the Dutch government decided not to ratify the Oviedo
Convention because of Article 18: BThe creation of human embryos for re-
search purposes is prohibited.^
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Table 2 Countries requiring genetic counseling
Country Types of genetic tests requiring genetic
counseling
Qualifications of medical professional Statute
Austria GT for:
• Determination of a manifested disease,
which is based on a germ line mutation
• Determination of predisposition for future
onset disease or carrier status for which a
prophylaxis or therapy is possible
• Determination of predisposition for future
onset disease or carrier status for which a
prophylaxis or therapy is not possible
• Prenatal diagnosis
Medical specialist with an education in human
genetics/medical genetics or a medical spe-
cialist competent for the respective special-
ty.
Austrian Gene Technology Act, Art 69
Cyprus • Prediction of disease
• Carrier GT
•GT detecting predisposition or susceptibility
to a disease
Not specified Law 31 (III)/2001 art. 12
Czech Republic GT for health purposes Not specified Act no 373/2011 Coll. On specific Health Care
Services
Estonia GT for health purposes Not specified Oviedo Convention
Finland GT for health purposes Not specified Oviedo Convention
France GT
• Giving, confirming or refuting the diagnosis
of a genetic disease
• Detecting characteristics of one or more
genes which may be the cause of
developing a disease
Geneticist or genetic counselor Arrêté de bonnes pratiques Juin 2013
Germany • Predictive GT, prenatal GT, fetal aneuploidy
risk assessment by non-invasive measures
(obligatory pre- and post-test counseling)
• Diagnostic GT (post-test counseling should
be offered. In case, the test result reveals an
untreatable disease, post-test counseling is
obligatory) performed)
Physician specialized in human genetics or
additionally qualified in medical genetics or
physician qualified in genetic counselling in
her or his area of practice either through
post-qualification professional training
(compulsory since February 2012) or during
specialty training (currently in preparation).
Genetic Diagnosis Act
Greece • GT predictive of disease
• Carrier GT
•GT detecting predisposition or susceptibility
to a disease
Not specified Law 2619/1998 art. 12
Hungary Genetic testing and screening Not specified Parliamentary Act No XXI of 2008 on the
protection of human genetic data, on the
human genetic studies on research and on
the operation of the biobanks. Amended by
the Act no CLXXVI of 2011 and by the
CXXVII of 2013.
Italy GT for:
• Health purposes
• Family reunion purposes
Physician or specialist in genetic medicine General Authorisation No. 8/2014 for the
Processing of Genetic Data by the Data
Protection Authority, point 5.1
Latvia GT for health purposes Not specified Oviedo Convention
Lithuania GT for health purposes Not specified Oviedo Convention
Norway • Presymptomatic GT
• Predictive GT
• Carrier GT
Not specified, but according to the preparatory
works (Ot.prp. No. 62 (2002–2002)) GT
should preferably be provided by specially
trained health personnel. If other kind of
health personnel carry out GT, the general
rule of professional responsibility and
diligent care apply.
Act of 5 December 2003 No 100 relating to the
application of biotechnology in human
medicine
Slovakia GT for health purposes Not specified Oviedo Convention
Slovenia • Predictive GT
• Carrier GT
• Predisposition/Susceptibility GT
• Prenatal GT
Clinical geneticist Act Ratifying the Convention for the
Protection of Human Rights and Dignity of
the Human Being with regard to the
Application of Biology and Medicine:
Convention on Human Rights and
Biomedicine, and of the Additional Protocol
to the Convention for the Protection of
Human Rights and Dignity of the Human
Being with regard to the Application of
Biology andMedicine, on the Prohibition of
J Community Genet (2018) 9:117–132 123
Austria, Belgium, Germany, Ireland and the UK have nei-
ther signed nor ratified the Oviedo Convention (Council of
Europe 2017a). Despite this fact, Austrian and German laws
provide a detailed framework for genetic counselling in the
context of genetic testing.
In Austria, the Austrian Gene Technology Act (hereinafter
GTG) makes the provision of genetic counselling mandatory
for certain categories of tests and provides detailed and strict
conditions for its provision (Gentechnikgesetz 1994, art. 69).
More specifically, certain types of genetic tests6 may only be
performed after the person taking the test has been informed
about the genetic test’s nature, consequences and significance.
This consultation should be non-directive and performed by a
medical specialist with an education in human genetics/medical
genetics or a medical specialist competent for the respective
specialty. The test may only be performed if the patient has
agreed to the genetic test as a result of a free consent based on
that knowledge. Post-test genetic counselling has to include a
comprehensive discussion of all test results andmedical facts as
well as possible medical, social and psychological conse-
quences. When it comes to genetic testing for predisposition
to a hereditary disease with serious physical, mental or social
consequences, an additional nonmedical counselling by a psy-
chologist or a psychotherapist or by a social worker should be
recommended to the patient in written form.
In Germany, according to the Genetic Diagnosis Act
(Gendiagnostikgesetz 2009) predictive genetic testing (sec.
10 para. 2), foetal aneuploidy risk assessment by non-
invasive methods and any prenatal genetic examination (sec.
15 para. 3) require pre- and post-genetic counselling. For di-
agnostic genetic examinations, post-test counselling should
merely be offered (sec. 10 para. 1). An obligation to perform
post-test genetic counselling exists only for test results refer-
ring to a condition for which no treatment is currently avail-
able. Genetic counselling may only be performed by physi-
cians who are specialists in human genetics, who are addition-
ally qualified in medical genetics or who are qualified in ge-
netic counselling in their area of practice through post-
qualification professional training (sec. 7 para. 3).
Are there specific requirements for informed consent that
may apply in the context of genetic testing?
Fourteen of the countries examined include specific provisions
regarding informed consent in the context of genetic testing
(Table 3). These countries are Austria, the Czech Republic,
France, Germany, Hungary, Ireland, Italy, Norway, Portugal,
Slovakia, Slovenia, Spain, Sweden and the UK.
For example, according to the German Genetic
Diagnosis Act (sec. 9 para. 2), the physician who intends
to undertake a genetic examination is under an obligation
to provide prior information to the patient regarding the
purpose, type, scope, and significance of the examination
and the anticipated meaningfulness of the results
(Gendiagnostikgesetz 2009). The information to be given
must also cover the potential health risks for the patient
associated with obtaining the sample and knowledge of
the test results. Moreover, the patient must be informed
about his/her right ‘not to know’. The patient is entitled to
withdraw his/her consent to the genetic examination and/
or to the disclosure of the results and to demand that they
be destroyed at any time before they are received. The
information must be summarised in a written document
before the examination takes place and appropriate time
for consideration must be granted to the subject person to
decide whether to consent or not (sec. 9 para. 1). An
essential precondition of the performance of a genetic ex-
amination is express written consent (sec. 8). Non-
compliance with this requirement is punishable by impris-
onment or a fine (sec. 25). The information must be given
orally but can be supplemented by written documents
(German Civil Code 1900, sec. 630e para. 2).
In France very specific provisions have been adopted to
ensure a particular protection of individuals with regard to the
prescription and information on results of genetic testing. Prior
information must be delivered to the patient by the physician
who is prescribing the analysis. This information concerns (1)
the characteristics of the sought disease, (2) the means of de-
tecting it and (3) the possibilities of prevention and treatment.
The information must be summarised in a written document
which could be used to inform the family members. Only the
prescribing medical doctor can deliver the information on the
results to the patient who has the right not to know. This infor-
mation must be included in the medical record.
6 Tests determining a manifested disease based on a germ line mutation, ge-
netic tests determining predisposition to a disease (especially future onset
diseases or the determination of carrier status), regardless whether prevention
or therapy is possible or not, as well as tests for prenatal diagnosis.
Table 2 (continued)
Country Types of genetic tests requiring genetic
counseling
Qualifications of medical professional Statute
Cloning Human Beings. UL RS 17/98., Art.
12
Spain GT for any health purposes By qualified personnel and carried in certified
centers
Act 14/2007, Art 55 and 56
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In Spain, the conditions for informed consent are regulated
for all genetic tests performed in a health context. According
to Act 14/2007 (Boletín Oficial del Estado No159 2007,
article 45 d and 48.1), the patient must receive written infor-
mation regarding: (1) the purpose of the genetic analysis; (2)
the place where the analysis shall take place and the way in
which the biological sample will be treated at the end of the
analysis, whether it is the disassociation of the identifying data
from the sample, its destruction or other treatments; (3) the
persons who will have access to the results of the analysis
when samples will not undergo a process of disassociation
or anonymisation; (4) a warning about the possibility of un-
expected findings and the possible implications for him or her,
as well as the patient’s right not to know; (5) a warning about
potential implications of this information for his or her family
members, and their interest, where appropriate, in having that
information conveyed to them; (6) an agreement to provide
genetic counselling, once the results of the analysis are obtain-
ed and evaluated.
In Hungary, the person undertaking a genetic test shall be
entitled to learn about the results of the human genetic exam-
ination in a consultation that is specifically tailored to his/her
needs (Parliamentary Act No XXI 2013). During the consul-
tation the person concerned shall be assisted in the long-term
processing of the possible consequences of the result and the
choice of optimum treatment opportunities.
Table 3 Countries requiring written informed consent specifically for genetic testing
Country Types of tests Statute
Austria GT for
• Determination of a manifested disease, which is based on a germ line
mutation
• Determination of predisposition for future onset disease or carrier
status for which a Prophylaxis or therapy is possible
• Determination of predisposition for future onset disease or carrier
status for which a prophylaxis or therapy is not possible
• Prenatal diagnosis
Austrian Gene Technology Act, Art 69
Czech Republic All GT Act No 373/2011 Coll. On Specific Health Care Services
France •Genetic tests provided for medical purposes including pre-transfer and
prenatal tests.
• Processing of genetic data for research.
Civil code, Art. 16-10, Public Health Code, Art. L 1131-1, Art. L
2131–4
Act N°78-17 of 6 January 1978 on Information Technology, Data Files
and Civil Liberties, Art. 56
Germany • GT for medical purposes
• GT to determine a family relationship
Genetic Diagnosis Act
Hungary All GT Parliamentary Act No XXI of 2008 on the protection of human genetic
data, on the human genetic studies on research and on the operation
of the biobanks. Amended by the Act no CLXXVI of 2011 and by
the CXXVII of 2013. Article 6 (4)
Ireland Informed consent is required for the processing of genetic data Disability Act 2005, Part 4, Section 41
Italy • Pre-symptomatic GT
• Susceptibility GT
General Authorisation No. 8/2014 for the Processing of Genetic Data
Norway All types of analyses of human genetic material at both nucleic acid and
chromosome level, analyses of genetic products and their function,
and examination of organs to obtain information on human genetic
constitution
Act of 5 December 2003 No. 100 relating to the application of
biotechnology in human medicine
Portugal GT for:
• The detection of the heterozygosity status of recessive diseases,
• The presymptomatic diagnosis of monogenic disease
• Genetic susceptibility in healthy individuals
Law no 12/2015
Slovakia All GT Act No 122/2013 Coll. On Personal Data Protection
Slovenia Health-related GT Act ratifying the Additional Protocol to the Convention on Human
Rights and Biomedicine concerning Genetic Testing for Health
Purposes, UL RS 14/09.
Spain GT performed in a health context Act 14/2007, Art 45 d) and 48.1
Sweden Genetic screening (not individual testing) The Genetic Integrity Act chapter 3, section 1 (2006:351)
UK The Act makes it an offence to carry out a genetic test without
Bqualifying consent^ with a small number of exceptions.
Consent may be written or oral.
According to the HTA’s website:
BAll companies providing DNA testing kits or DNA testing services
must comply with the provisions of the Human Tissue Act 2004
relating to consent and the holding of bodily material with the intent
to analyze DNA.^a
Human Tissue Act 2004 (s 45 (1)(a)(i)
a HTA, ‘Analysis of DNA under the HTAct FAQs’ https://www.hta.gov.uk/faqs/analysis-dna-under-ht-act-faqs accessed 10 October 2016
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The Czech Republic (Act No. 373/2011 Coll. 2011) and
Slovenia (UL RS 17/98 1998) mandate that written informed
consent is a prerequisite for all genetic tests. On the same line,
Ireland (Disability Act 2005) and Slovakia (Act No. 373/2011
Coll. 2011) require informed consent for the ‘processing’ of
genetic data.
Other countries, such as Austria, Portugal, and Norway
require written informed consent only for specific categories
of genetic tests. More specifically, in Austria, genetic tests
determining a manifested disease based on a germ line muta-
tion, genetic tests determining predisposition to a disease (es-
pecially future onset diseases or the determination of carrier
status), as well as genetic tests for prenatal diagnosis, are only
allowed to be performed upon written consent of the person to
be tested within the context of the genetic counselling as de-
scribed above. The informed consent form should indicate that
the patient has been informed in advance about the genetic
test’s nature, consequences and significance. The information
should be provided by a medical specialist with an education
in human genetics/medical genetics or a medical specialist
competent for the respective specialty (Gentechnikgesetz
1994, article 69).
In Portugal (Law n 12/2005 2005, article 9.2),7 detecting
heterozygosity status of recessive diseases, diagnosing mono-
genic diseases and testing for genetic susceptibility in healthy
individuals may only be carried out upon explicit written in-
formed consent of the person undertaking the examination
(Borry et al. 2012). In Norway, written consent shall be ob-
tained from the person concerned, before presymptomatic,
predictive and carrier genetic tests are undertaken (The
Patients’ Rights Act 1999, d sect. 5-1, second paragraph, litra
b). Before such testing is carried out, the Ministry shall give
separate authorization for each disease or predisposition to a
disease that is to be tested (The Patients’ Rights Act 1999,
sect. 5-3). In Sweden, written consent is required for genetic
tests that are carried out as part of a medical screening (Lag
(2006:351) 2006, section 1) (but not necessarily if it is a ser-
vice provided to one person based on individual needs).
In countries where specific informed consent rules regard-
ing genetic testing are not in place, general laws may apply in
this context, many of them related to patient’s rights and doc-
tor’s obligations.
For example, in Denmark, if a medical doctor or another
licensed healthcare professional is involved in (DTC) genetic
testing, the general obligation to provide due care applies and
so do the provisions in the Danish Act on Health regarding
patients’ right to information, consent and privacy. Although
these rules are not specifically targeting genetic testing, they
have an impact on, for example, the right to information both
before and after the test, the right not to know as well as
protection of genetic information and regulation of access to
and disclosure of information both within the healthcare ser-
vices and to third parties. The Act on Health also contains
special provisions regarding young patients’ right to self-
determination and proxy consent in regard to children and
non-autonomous adults, which are of importance for genetic
testing.
On the same line, according to the Dutch ‘Medical
Treatment Contracts Act’, (laying down the rights and obliga-
tions of care providers and patients, as well as, in certain
situations, customers) healthcare providers should provide in-
formation about the indication, the proposed treatment, alter-
natives, prognoses have, risks and possible side effects before
starting a medical intervention. Furthermore, a healthcare
worker always needs informed consent of the patient in order
to perform any test, including a genetic test. The patient can
also decide that he/she wishes to be spared certain information
or the results.
Discussion
To what extent do these laws affect DTC genetic testing?
Based on the above information, it is evident that European
countries follow different approaches when it comes to regu-
lation of genetic testing and impose various levels of restric-
tions. On the one end of the spectrum is France, which essen-
tially bans DTC genetic testing, by limiting the use of genetic
testing to specific health-related tests, mandating the involve-
ment of healthcare professionals and penalizing users of tests
that do not fulfil these conditions. Similarly, Germany has
legislation that has been considered by some as targeting
DTC genetic testing and limiting the access German con-
sumers may have to this type of testing (EASAC and FEAM
Working Group 2012; C. Wright 2009). On the other end are
many countries that do not provide any specific legislation on
genetic testing (such as Luxembourg, Poland and Romania),
and, as a result, the only restrictions in place are those based
on more general laws, usually regarding healthcare services
and patients’ rights.
It is worth noticing that the aspects of genetic testing that
this article particularly addresses, namely medical supervi-
sion, genetic counselling and informed consent, are closely
connected and often overlap in practice. For example, it is
often the case that informed consent is obtained from the pa-
tient during a genetic consultation performed by a healthcare
professional who may have also prescribed the test. When it
comes to health-related genetic testing, medical supervision,
genetic counselling and informed consent have some funda-
mentally similar goals, namely to guide users to make deci-
sions about their health based on genetic tests that are
7 Portugal ratified the Oviedo Convention through Presidential Decree n 01/
2001, which means that the Convention has now the force of law in the
national territory.
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appropriate for them, after understanding their benefits, limi-
tations and possible implications. The close connection of
these notions can be noticed in some national laws that do
not address these aspects separately. In many jurisdictions
(for example in Sweden and Ireland), despite genetic counsel-
ling not being specifically addressed, its necessity may be
implied by provisions relevant to informed consent. This is
because it may be argued that, in the context of genetic testing,
unless genetic counselling takes place, consent cannot really
be informed.
Most of the above-mentioned laws apply to genetic testing
offered within the conventional healthcare system, where lab-
oratories and clinical services are subject to professional bod-
ies and internal controls (C. F. Wright et al. 2011). Applying
the same laws in the commercial sector, outside of a clinic or
hospital may be more complicated.
While in some cases (such as in the case of Germany,
France (Abbasi and Rial-Sebbag 2012) and Spain) even if
the laws do not explicitly refer to the commercial context, it
seems to be evident that the law restricts the provision of DTC
genetic tests. InHungary, the Genetic Act of 2008 has a broad
scope, originally tailored to the public healthcare system, but it
also applies to private companies operating in Hungary in that
it explicitly regulates the type of tests that are allowed. In other
countries, however, it is not clear whether the law only regu-
lates the genetic testing process within the clinic or whether
relevant provision could be the basis for banning or limiting
DTC companies from marketing their products in specific
European countries (Grimaldi et al. 2011).
In theUK, the distinction between the regulation of genetic
testing within the clinical setting and the provision of genetic
testing DTC seems to be clearer. While in the clinical setting
there is medical supervision and genetic counselling available,
DTC genetic testing (that often does not fulfil those require-
ments) is currently not prohibited in the country. A number of
companies are selling DTC services to UK consumers and
23andMe is currently selling its kits both through its website
and through the pharmaceutical chain Superdrug (GeneWatch
UK 2015). A similar approach also applies in Estonia where
various nutrigenetic and health-related diagnostic8 tests are
sold via pharmacy chains. However, all prenatal tests for the
diagnosis and treatment of diseases listed in International
Statistical Classification of Diseases and Related Health
Problems Tenth Revision (ICD-10) are carried out only in
clinical centres as health service according to the Health
Services Organisation Act.
Another crucial point to be taken into account when consid-
ering whether some laws apply to DTC genetic tests is whether
these tests are considered to be health services or not. DTC
genetic testing often blurs the lines between medical devices
and consumer products. In some cases, it is unclear whether
providing these kinds of services may constitute practice of med-
icine or not. The answer to this question may determine whether
several national laws, such as the Health and Medical Services
Act and the Genetic Integrity Act that regulates uses of certain
biotechnology for medical purposes in Sweden, the Medical
Treatment Law in Latvia and the Act on Authorization of
Healthcare Professionals inDenmark, as well as various national
laws related to patients’ rights, apply in this context.
A straightforward answer is not evident; this is because
there is no uniform definition across European countries of
what constitutes ‘practice of medicine’. This matter is usually
left to national medical licensing authorities to decide
(Marietta and Mcguire 2009). In addition, the distinction be-
tween health-related and non-health related tests is not always
clear. Health-related tests have been given various definitions.
For example, Goddard et al. define them as tests that aim ‘to
predict risk of disease, screen for disease, direct clinical man-
agement, identify carriers, or establish prenatal diagnoses,
clinical diagnoses, or prognoses in individual people or fam-
ilies’ (Goddard et al. 2008). There are several types of genetic
tests that, despite not falling in the above mentioned catego-
ries, can still have an (indirect or direct) impact on health, such
as nutrigenomic tests (Grimaldi et al. 2011). Moreover, many
of the ‘packages’ of tests currently available provide medical,
genealogical and recreational information at the same time,
challenging the distinction between medical and lifestyle de-
vices (Lucivero and Prainsack 2015; Prainsack et al. 2008). At
the same time, this matter is further complicated by the rhe-
toric adopted by many DTC genetic testing companies, which
often underplays the health implications of their services and
stresses the ‘informational’ and ‘fun’ aspects of their services
(Kalokairinou et al. 2017).
A further challenge for the effective regulation of DTC
genetic testing is the fact that these tests are mostly sold
through the internet and hence where different jurisdictions
begin or end is difficult to clearly delineate. DTC genetic
testing companies may be based anywhere in the world, and,
indeed, most of them are based outside Europe. As a result,
even if a test is sent to a specific European country, the regu-
lation of this service may (or may not) still fall outside the
national jurisdiction. For example, in Norway, the Act of 5
December 2003 No 100, relating to the application of biotech-
nology in humanmedicine stipulates in regard to the territorial
scope that it ‘applies within the realm’. As a result, providers
operating abroad would clearly fall outside the territorial
scope of the act, even if the enterprise is directly targeting
the Norwegian market. Moreover, even if these services fall
within the scope of national laws, their enforcement may be
rather challenging. This is because, as Hauskeller has claimed,
‘A globally acting, internet based industry cannot be forced to
comply with laws or regulations that are binding only country
by country’ (Hauskeller 2011).
8 It should be noted that various diagnostic test-kits are not at all genetic tests
but antibody detecting kits.
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It should be also noted that besides laws related to medical
supervision, genetic counselling and informed consent, DTC
genetic testing companies may encounter additional regulato-
ry barriers when selling their products in some European
countries. For example, in the Netherlands, the Dutch Act
on Population Screening (Wet op het bevolkingsonderzoek
1992) may require such companies to obtain a license before
offering their products to the Dutch population. According to
this Act, a population screening is a medical examination car-
ried out in response to an offer made to the entire population or
to a section thereof, in order to detect certain diseases or risk
indicators. Screenings that use ionizing radiation, for (risk-
indicators for) cancer and untreatable diseases require a li-
cense by the Minister of Health, Welfare and Sports due to
their potential health risks.9 Commercial companies offering
such genetic tests DTC may fall within the scope of the Act,
since ‘offer’ in this context may not be limited to actively
inviting individuals, but also the passive ‘seduction’ of people
via advertisements.
Finally, it should be underlined that the practical impact of
such laws on DTC genetic companies is difficult to be pre-
cisely estimated. Currently, some companies, such as
23andMe only market their products to specific European
countries, possibly in order to avoid legal repercussions in
countries with more restrictive regulatory framework.
However, while in the US, there have been several legal ac-
tions against DTC genetic testing companies both by govern-
mental bodies, such as the Food and Drug Administration
(FDA 2013) and the Federal Trade Commission (US Federal
Trade Commission 2014), as well as by consumers (Munro
2013), we are not aware of similar legal actions having been
taken in the countries covered by our study.
A missed opportunity for a harmonized regulatory
framework?
The current fragmented regulatory framework across Europe
regarding medical supervision, genetic counselling and in-
formed consent as well as the uncertainties regarding the
scope of application of national laws brings up the question
of whether a harmonized European regulation would be
desirable.
This question became particularly topical during the revi-
sion process of the Medical Devices Directives (European
Commission 2017). This process led to the adoption, on 5th
April 2017, of the Regulation on IVD medical devices, which
will replace the IVD Directive. During the ordinary legislative
procedure (European Parliament 2015), the European
Parliament issued a proposal suggesting that this instrument
should also regulate aspects related to medical supervision,
genetic counselling and informed consent (Committee on the
Environment Public Health and Food Safety 2013). More
specifically, the European Parliament’s proposal suggested,
among others, that all genetic tests with a direct or indirect
medical purpose should be classified as prescription only de-
vices, and that their DTC advertising should be forbidden. In
addition, it was proposed that genetic counselling should be
mandatory for predictive, prenatal and diagnostic genetic
tests. The counselling for this kind of tests, according to the
proposal, should be intelligible and cover medical, ethical,
social, psychological and legal aspects, while informed con-
sent should be written (Committee on the Environment Public
Health and Food Safety 2013; Kalokairinou et al. 2015). The
adoption of these amendments would have effectively sig-
nalled a ban on most types of DTC genetic testing. Such a
ban would have been uniformly implemented across Europe,
since Regulations, as opposed to Directives are directly bind-
ing for Member States, without the need of being transposed
into the national legislation (European Union 2017).
The proposal received strong criticism regarding these
amendments. The criticism was mostly focused on whether
the EU has the competence to enact such amendments and
whether the amendments would actually be beneficial for clin-
ical practice. A legal opinion issued by members of the
Alliance of European Life Science Law Firms (hereinafter
the Alliance Opinion) (Alliance of European Life Sciences
Law Firms 2014) stated that the amendment on informed con-
sent and genetic counselling of the proposal would infringe
the principles of proportionality and subsidiarity, established
by the Treaty on the Functioning of the European Union.
According to these principles, the EU may only take legisla-
tive action in cases where the objectives of the legislation may
be achieved more effectively at an EU level rather than at a
Member State level, by reason of the scale or effects of its
proposed action (Alliance of European Life Sciences Law
Firms 2014; European Union 2012). According to the
Alliance Opinion, there is no evidence that the amendments
suggested by the Parliaments’ proposal reflected these princi-
ples. These amendments were perceived by many as an at-
tempt to regulate medical practice through regulation on de-
vices (Eurogentest 2014), since the aim of the Regulation on
IVD medical devices is the same as this of the Directive: to
enhance the smooth functioning of the internal market and to
prevent IVD devices that are not safe and efficient from en-
tering the market.
Furthermore, several stakeholders pointed out the potential
negative results of imposing uniform strict criteria in clinical
practice across Europe. In this regard, it was mentioned that
potential adoption of such legislation ‘will mark an unprece-
dented interference by the European Union in clinical
practice’(Eurogentest 2014) and the European Society of
Human Genetics considered them to be ‘unworkable in in
9 Such license may be granted when the population screening is scientifically
sound, in accordance with the professional medical practice standard (in-
formed consent, genetic counseling) and the expected benefits offset the risks
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the daily practice of medicine’. This is largely because, as also
indicated by our results, clinical practice is organized in dif-
ferent ways across Europe. It was considered that imposing
detailed arrangements for every clinic would
restrict legitimate, ethically acceptable genetic testing
activities such as newborn screening and fetal sex deter-
mination, and they infringe on accepted and acceptable
clinical practice when they should be regulating IVDs,
effectively high-jacking a sound and important directive
to interfere with carefully regulated clinical practice and
infringing on patients’ autonomy (Eurogentest 2014).
Amid those reactions, the original amendments proposed
by the European Parliament regarding medical supervision,
genetic counselling and informed consent where not included
in the final document of the Regulation on IVD medical de-
vices. The text voted by European Parliament mentioned in
the recitals:
It appears that divergent national rules regarding the
provision of information and counselling in relation to
genetic testing may only have an impact on the smooth
functioning of the internal market to a limited extent.
Therefore, it is appropriate to lay down only limited
requirements in this regard in the present regulation,
having regard to the need to ensure constant respect of
the principles of proportionality and subsidiarity
(European Parliament and the Council of the EU 2016).
In this text, the proposed amendment according to which
genetic tests should be classified as prescription-only medical
devices is omitted. When it comes to informed consent, the
newly adopted Article 4a on ‘Genetic information, counsel-
ling and informed consent’ stipulates that genetic tests per-
formed in context of healthcare and for the medical purpose
of diagnostics, improvement of treatments, predictive or pre-
natal testing, the individual undergoing testing should receive
relevant information regarding the nature, the significance and
the implication of the test. Furthermore, the same article stip-
ulates that Member States shall ensure appropriate access to
genetic counselling for tests that provide information on the
genetic predisposition for medical conditions and/or diseases
perceived to be untreatable based on the state of science and
technology (European Parliament and the Council of the EU
2016). The Regulation also explicitly mentions that Member
States should be free to adopt or maintain in their national
legislation more protective provisions regarding informed
consent and genetic counselling and national laws classifying
specific IVD devices as requiring a medical prescription shall
not be affected.
The approach taken in the final text of the Regulation
seems to be rather pragmatic: the Regulation focuses on its
main aimwhich is the safety and performance of IVD devices.
At the same time, the Regulation places more emphasis on
genetic counselling and informed consent compared to the
Directive, while leaving Member States leeway to adapt those
requirements in their clinical practice. While aspects related to
genetic tests as products, such as their clinical validity, will be
uniformly regulated by the new Regulation on IVD medical
devices in order to enhance the smooth functioning of the
internal market, medical supervision, genetic counselling
and informed consent are aspects closely related to the clinical
practice of each Member State.
A harmonized regulatory approach across Europe on med-
ical supervision, genetic counselling and informed consent for
genetic testing may contribute to a more effective oversight of
DTC genetic testing services and potentially minimize some
of the risks associated with such services. However, the pro-
visions suggested during the debate on the adoption of the
Regulation on IVD medical devices, would have also resulted
in essential changes in the clinical practices of Member States,
which were considered by many unworkable and have been
unwelcomed by several stakeholders.
While, these developments may be perceived by some as a
missed opportunity towards a uniform pan-European regula-
tory framework, imposing strict uniform standards of in-
formed consent, genetic counselling and medical supervision
by means of an EU Regulation, seems, impractical and restric-
tive and beyond the legislative competence of the EU.While it
is important to ensure equal level of protection of patient rights
across Europe, including availability of genetic counselling
and medical supervision, as well as adequate informed con-
sent processes, such standards can be achieved by Member
States following the Additional Protocol on genetic testing for
health purposes (Council of Europe 2008) and relevant inter-
national and European guidelines (European Society of
Human Genetics 2010; Organisation for Economic Co-
operation and Development 2007). Furthermore, emphasis
should be placed in coordinating efforts for the harmonization
of genetic testing guidelines across Europe.
Limitations
This article aims to give a general overview of national legis-
lations addressing genetic testing, but it should not be consid-
ered as providing an exhaustive list of applicable legislation.
Different interpretations of the laws than the ones provided in
this article may be possible. This is because, as discussed in
this article, DTC genetic testing is regulated by national laws
applying to such products by analogy. The applicability of
relevant legislation is further complicated by the fact that
DTC genetic testing is provided outside the traditional
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healthcare system, blurring the lines between medical and
recreational products. Furthermore, DTC genetic tests are
mostly sold through the internet, raising questions regarding
jurisdiction and enforcement.
Conclusion
We provide herein an overview of 26 European countries’
national legislations addressing the topics of medical supervi-
sion, genetic counselling and informed consent in the context
of genetic testing. The results clearly demonstrate that there is
a large heterogeneity in the way these different countries have
chosen to regulate these aspects of genetic testing.
Furthermore, we have discussed the potential impact of these
legislations on DTC genetic testing; with highly varying
levels of restrictions, some countries would appear to
(almost) ban DTC genetic testing, while others do not appear
to have much regulatory framework for this model of provi-
sion. With a steadily increasing number of companies and
different tests sold, such an overview provides a rich resource
that can be used to further understand the legal landscape in
Europe and to potentially identify different legislative tools
that may be useful in helping guide DTC genetic testing com-
panies to act responsibly.
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